☆ 4.7 Article

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

ISCIENCE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

添加到收藏夹

Letter Medicine, General & Internal

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Immunology

Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant

Aurelien Sokal et al.

Summary: The Omicron variant of SARS-CoV-2 is able to escape neutralization by antibodies elicited by vaccines and previous infection. However, the memory B cells (MBCs) generated by mRNA vaccines can still recognize and neutralize the Omicron variant to some extent, providing a certain level of protection for vaccinated individuals.

IMMUNITY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19

Ilias Giannakodimos et al.

Summary: The newly identified virus SARS-CoV-2 caused the COVID-19 pandemic, showing similarities with MERS and SARS. IL-6 plays a key role in the pathogenesis and treatment of COVID-19, with TCZ being a viable therapeutic option.

CURRENT MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery

Chengqian Feng et al.

Summary: The study found that SARS-CoV-2 specific immune response can persist to some extent up to 1 year after recovery from COVID-19, with serum neutralizing capacity decreasing but remaining stable. Viral-specific cellular immune protection persists between 6 months and 12 months after recovery.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Letter Medicine, General & Internal

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19 A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette et al.

Summary: This follow-up study explores the relationship between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

Mathilde Roumier et al.

Summary: Treatment with tocilizumab in patients with severe COVID-19 pneumonia showed reduced need for overall ventilatory support, an increased rate of oxygen withdrawal, and higher discharge rate at D28. However, there was no significant improvement in overall survival. Higher rates of neutropenia were observed in the tocilizumab group, while rates of infections, including ventilator-acquired pneumonia, were higher in the control group. These findings could guide future trials aimed at managing COVID-19-induced inflammation, particularly before ICU admission.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection

Bong-Ha Shin et al.

TRANSPLANTATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial

Chao Zhang et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm

Chuang Guo et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Immunology

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients

Renata Varnaite et al.

JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Immunology

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Matthew C. Woodruff et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study

Mar Masia et al.

EBIOMEDICINE (2020)

添加到收藏夹

Article Immunology

B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients

Victor A. Sosa-Hernandez et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Rheumatology

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Ajinkya Pawar et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Editorial Material Microbiology

The Role of Interleukin 6 During Viral Infections

Lauro Velazquez-Salinas et al.

FRONTIERS IN MICROBIOLOGY (2019)

添加到收藏夹

Article Rheumatology

CD27-IgD-memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis

Zafar Mahmood et al.

ARTHRITIS RESEARCH & THERAPY (2015)

添加到收藏夹

Article Rheumatology

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

Meliha C. Kapetanovic et al.

ARTHRITIS RESEARCH & THERAPY (2014)

添加到收藏夹

Review Immunology

Cytokine-meciated regulation of plasma cell generation: IL-21 takes center stage

Leen Moens et al.

FRONTIERS IN IMMUNOLOGY (2014)

添加到收藏夹

Article Rheumatology

Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis

Shunsuke Mori et al.

ANNALS OF THE RHEUMATIC DISEASES (2012)

添加到收藏夹

Article Oncology

Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody

Caroline Galeotti et al.

MOLECULAR CANCER THERAPEUTICS (2012)

添加到收藏夹

Article Rheumatology

Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells

Khalid Muhammad et al.

ANNALS OF THE RHEUMATIC DISEASES (2011)

添加到收藏夹

Article Rheumatology

In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab on the B Cell Compartment

Petra Roll et al.

ARTHRITIS AND RHEUMATISM (2011)

添加到收藏夹

Article Rheumatology

Tocilizumab in Systemic Lupus Erythematosus Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study

Gabor G. Illei et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Article Hematology

IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production

Kenichiro Maeda et al.

BLOOD (2010)

添加到收藏夹

Article Immunology

Circulating Antibody-Secreting Cells during Acute Respiratory Syncytial Virus Infection in Adults

F. Eun-Hyung Lee et al.

JOURNAL OF INFECTIOUS DISEASES (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.